|
Royalty Pharma Plc (RPRX) |
|
|
|
RPRX's Operating Income Growth by Quarter and Year
Royalty Pharma Plc's Operating Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
RPRX Operating Income (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
IV Quarter |
December |
612.90
|
-482.66
|
153.42
|
677.40
|
III Quarter |
September |
151.44
|
192.21
|
303.05
|
510.57
|
II Quarter |
June |
248.84
|
377.79
|
744.95
|
409.35
|
I Quarter |
March |
478.97
|
219.72
|
229.30
|
-1.91
|
FY |
|
1,492.15
|
307.06
|
1,430.72
|
1,595.41
|
RPRX Operating Income fourth quarter 2023 Y/Y Growth Comment |
Royalty Pharma Plc in the fourth quarter 2023 achieved Operating Income of $ 612.90 millions compare to Operating Loss recorded in same quarter a year ago.
Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Operating Income growth. While Royalty Pharma Plc' s Operating Income no change of % ranks overall at the positon no. 871 in the fourth quarter 2023.
Explain Operating Income growth
|
RPRX Operating Income ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
- |
- |
-77.35 % |
- |
III Quarter |
September |
-21.21 % |
-36.57 % |
-40.64 % |
- |
II Quarter |
June |
-34.13 % |
-49.29 % |
81.98 % |
- |
I Quarter |
March |
117.99 % |
-4.18 % |
- |
- |
FY |
|
385.95 % |
-78.54 % |
-10.32 % |
- |
RPRX Operating Income (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
304.71 % |
- |
-49.37 % |
32.68 % |
III Quarter |
September |
-39.14 % |
-49.12 % |
-59.32 % |
24.73 % |
II Quarter |
June |
-48.05 % |
71.94 % |
224.88 % |
- |
I Quarter |
March |
- |
43.21 % |
-66.15 % |
- |
FY (Year on Year) |
|
385.95 % |
-78.54 % |
-10.32 % |
- |
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
441.46 % |
50.02 % |
-78.54 % |
(Jun 30 2021) |
|
(Dec 31 2022) |
|
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
441.46 % |
50.02 % |
-78.54 % |
(Jun 30 2021) |
|
(Dec 31 2022) |
|
Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Royalty Pharma Plc's Q/Q Operating Income Growth
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
304.71 % |
32.58 % |
-66.15 % |
(Dec 31 2023) |
|
|
RPRX's IV. Quarter Q/Q Operating Income Comment |
Royalty Pharma Plc achieved in the IV. Quarter 2023 above company average sequential Operating Income doubling of 304.71%, to $ 612.90 millions, from $151.44 millions in the third quarter. Royalty Pharma Plc is impressively improving, not just recording higher then normal gain, and additionally accelerating speed, Dahnya López , Major Pharmaceutical Preparations industry expert added.
Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Operating Income growth. While Royalty Pharma Plc's Operating Income growth quarter on quarter, overall rank is 56. |
|
|
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
304.71 % |
32.58 % |
-66.15 % |
(Dec 31 2023) |
|
|
RPRX's IV. Quarter Q/Q Operating Income Comment |
Royalty Pharma Plc achieved in the IV. Quarter 2023 above company average sequential Operating Income doubling of 304.71%, to $ 612.90 millions, from $151.44 millions in the third quarter. Royalty Pharma Plc is going from strength to strength, not just recording higher then normal growth, and additionally accelerating rate, Dahnya López , Major Pharmaceutical Preparations industry expert said.
Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Operating Income growth. While Royalty Pharma Plc's Operating Income growth quarter on quarter, overall rank is 56. |
|
Royalty Pharma Plc's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending (Dec 31 2023) |
12 Months Ending (Sep 30 2023) |
12 Months Ending (Jun 30 2023) |
12 Months Ending (Mar 31 2023) |
12 Months Ending (Dec 31 2022) |
Cumulative Operating Income 12 Months Ending |
$ 1,492.15 |
$ 396.60 |
$ 437.37 |
$ 566.32 |
$ 307.07 |
Y / Y Operating Income Growth (TTM) |
385.94 % |
-57.95 % |
-58.5 % |
-60.15 % |
-78.54 % |
Year on Year Operating Income Growth Overall
Ranking |
# 890 |
# 1832 |
# 1837 |
# 1618 |
# 1555 |
Seqeuential Operating Income Change (TTM) |
276.24 % |
-9.32 % |
-22.77 % |
84.43 % |
-67.44 % |
Seq. Operating Income Growth (TTM) Overall
Ranking |
# 871 |
# 1281 |
# 1603 |
# 1224 |
# 1775 |
Cumulative Operating Income growth
Comment |
Royalty Pharma Plc saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 385.94% year on year, to $ 1,492 millions if the fiscal year would have ended in Dec 31 2023. Royalty Pharma Plc's trailing twelve months Operating Income growth was higher than company's average 50.02% and higher than -57.95% growth in Sep 30 2023. But from twelve months ended Sep 30 2023 rise was less at 276.24 % from $396.6 millions recorded in twelve months ending a quarter Sep 30 2023 Dahnya López added on. Yet it was confirmation of strength, as the average Q/Q TTM Operating Income growth is at 50.02%. The growth was even higher from the previous reporting period clinched at 276.24 % increase from $396.6 millions in twelve months ending a quarter before.
In the Healthcare sector 68 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 890, from total ranking in previous quarter at 1832. |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
441.46 % |
50.02 % |
-78.54 % |
|
|
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
441.46 % |
50.02 % |
-78.54 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 21 |
Sector |
# 69 |
S&P 500 |
# 871 |
|
Cumulative Operating Income growth
Comment |
Royalty Pharma Plc saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 385.94% year on year, to $ 1,492 millions if the fiscal year would have ended in Dec 31 2023. Royalty Pharma Plc's trailing twelve months Operating Income growth was higher than company's average 50.02% and higher than -57.95% growth in Sep 30 2023. But sequential rise was beneth at 276.24 % from $396.6 millions recorded in the period from Sep 30 2023 to Dec 31 2022 Dahnya López went on. Still this was validation of strength, as the typical sequential gain stands at 50.02%. The growth was even stronger from the previous reporting period clinched at 276.24 % rise from $396.6 millions in twelve months ending a quarter Sep 30 2023.
In the Healthcare sector 68 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 890, from total ranking in previous quarter at 1832. |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
441.46 % |
50.02 % |
-78.54 % |
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
441.46 % |
50.02 % |
-78.54 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 21 |
Sector |
# 69 |
S&P 500 |
# 871 |
|